Danusertib PHA-739358

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Danusertib PHA-739358	Purity：98% min
CAS NO：827318-97-8	Solubility：DMSO : 50 mg/mL (105.36 mM)
Molecular Formula：C₂₆H₃₀N₆O₃	Package：Package according to customer requirements.
Molecular Weight：474.555	Storage：Store at -20ºC

Quality control

COA

Remarks

Danusertib, also known as PHA-739358, is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Aurora kinase inhibitor PHA-739358 binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. This agent may preferentially bind to and inhibit Aurora B kinase. Aurora kinases, a family of serine-threonine kinases, are important regulators of cellular proliferation and division.

FGFR Inhibitors Related Products:

Infigratinib; PD173074; AZD4547; Brivanib alaninate; Pemigatinib; Lenvatinib; Lenvatinib mesylate; Nintedanib esylate; BLU9931; SKLB610 ; Roblitinib

References

[1]. Zi D, et al. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells. Int J Mol Sci. 2015 Nov 13;16(11):27228-51.

[2]. Gontarewicz A, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008 Apr 15;111(8):4355-64.